Search Results - "PODZAMCZER, Daniel"

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study by Raffi, Francois, Prof, Rachlis, Anita, Prof, Stellbrink, Hans-Jürgen, Prof, Hardy, W David, MD, Torti, Carlo, MD, Orkin, Chloe, MD, Bloch, Mark, MD, Podzamczer, Daniel, MD, Pokrovsky, Vadim, Prof, Pulido, Federico, MD, Almond, Steve, MMath, Margolis, David, MD, Brennan, Clare, DPT, Min, Sherene, MD

“…Summary Background Dolutegravir (S/GSK1349572) is a once-daily HIV integrase inhibitor with potent antiviral activity and a favourable safety profile. We…”
Get full text

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials by Sax, Paul E, Dr Prof, Wohl, David, MD, Yin, Michael T, Prof, Post, Frank, MD, DeJesus, Edwin, MD, Saag, Michael, MD, Pozniak, Anton, MD, Thompson, Melanie, MD, Podzamczer, Daniel, MD, Molina, Jean Michel, Prof, Oka, Shinichi, MD, Koenig, Ellen, MD, Trottier, Benoit, MD, Andrade-Villanueva, Jaime, MD, Crofoot, Gordon, MD, Custodio, Joseph M, PharmD, Plummer, Andrew, MS, Zhong, Lijie, PhD, Cao, Huyen, MD, Martin, Hal, MD, Callebaut, Christian, PhD, Cheng, Andrew K, MD, Fordyce, Marshall W, MD, McCallister, Scott, MD

“…Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide…”
Get full text

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial by Santos, José R., Saumoy, María, Curran, Adrian, Bravo, Isabel, Llibre, Josep M., Navarro, Jordi, Estany, Carla, Podzamczer, Daniel, Ribera, Esteban, Negredo, Eugènia, Clotet, Bonaventura, Paredes, Roger

“…Background. It is unknown if tenofovir disoproxil fumarate (TDF), which is often coformulated with the lipid-neutral emtricitabine (FTC), has a lipid-lowering…”
Get full text

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent by JING YUAN, SHENG GUO, PODZAMCZER, Daniel, HAAS, David W, HALL, David, CAMMETT, Anna M, JAYADEV, Supriya, DISTEL, Manuel, STORFER, Stephen, ZIMEI HUANG, MOOTSIKAPUN, Piroon, RUXRUNGTHAM, Kiat

“…Nevirapine is widely prescribed for HIV-1 infection. We characterized relationships between nevirapine-associated cutaneous and hepatic adverse events and…”
Get full text

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial by Arribas, José R, Dr, Girard, Pierre-Marie, MD, Landman, Roland, MD, Pich, Judit, PharmD, Mallolas, Josep, MD, Martínez-Rebollar, María, MD, Zamora, Francisco X, MD, Estrada, Vicente, MD, Crespo, Manuel, MD, Podzamczer, Daniel, MD, Portilla, Joaquín, MD, Dronda, Fernando, MD, Iribarren, José A, MD, Domingo, Pere, MD, Pulido, Federico, MD, Montero, Marta, MD, Knobel, Hernando, MD, Cabié, André, Prof, Weiss, Laurence, Prof, Gatell, José M, Prof

“…Summary Background Our objective was to assess therapeutic non-inferiority of dual treatment with lopinavir–ritonavir and lamivudine to triple treatment with…”
Get full text

Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study by Di Yacovo, Silvana, Saumoy, Maria, Sanchez-Quesada, Jose Luis, Navarro, Antonio, Sviridov, Dmitri, Javaloyas, Manuel, Vila, Ramon, Vernet, Anton, Low, Hann, Penafiel, Judith, Garcia, Benito, Ordonez-Llanos, Jordi, Podzamczer, Daniel

“…Objective To assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate…”
Get full text

Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018 by Domínguez-Domínguez, Lourdes, Rava, Marta, Bisbal, Otilia, Lopez-Cortés, Luis, Portilla, Joaquín, Podzamczer, Daniel, Olalla, Julián, Fuster, Daniel, Rubio, Rafael, Jarrín, Inmaculada, Iribarren, José Antonio, Moreno, Santiago

“…To study whether the association between the CD4/CD8 ratio variation over time and the development of clinical outcomes vary in late presenters (CD4 count <…”
Get full text

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144 by Wang, Ruolan, Wright, Jonathan, Saggu, Parminder, Ait-Khaled, Mounir, Moodley, Riya, Parry, Chris M, Lutz, Thomas, Podzamczer, Daniel, Moore, Richard, Górgolas Hernández-Mora, Miguel, Kinder, Clifford, Wynne, Brian, van Wyk, Jean, Underwood, Mark

“…The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir…”
Get full text

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption by Rockstroh, Jürgen K, Asmuth, David, Pantaleo, Giuseppe, Clotet, Bonaventura, Podzamczer, Daniel, van Lunzen, Jan, Arastéh, Keikawus, Mitsuyasu, Ronald, Peters, Barry, Silvia, Nozza, Jolliffe, Darren, Ökvist, Mats, Krogsgaard, Kim, Sommerfelt, Maja A

“…Vacc-4x, a therapeutic HIV vaccine candidate has previously induced a significant reduction in viral load (VL) set-point compared to placebo upon interruption…”
Get full text

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study by Orkin, Chloe, MD, DeJesus, Edwin, MD, Ramgopal, Moti, MD, Crofoot, Gordon, MD, Ruane, Peter, MD, LaMarca, Anthony, MD, Mills, Anthony, MD, Vandercam, Bernard, MD, de Wet, Joseph, MD, Rockstroh, Jürgen, MD, Lazzarin, Adriano, MD, Rijnders, Bart, MD, Podzamczer, Daniel, MD, Thalme, Anders, MD, Stoeckle, Marcel, MD, Porter, Danielle, PhD, Liu, Hui C, PhD, Cheng, Andrew, MD, Quirk, Erin, MD, SenGupta, Devi, MD, Cao, Huyen, Dr

“…Summary Background Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fumarate,…”
Get full text

HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation by Rosado-Sánchez, Isaac, Herrero-Fernández, Inés, Genebat, Miguel, Del Romero, Jorge, Riera, Melchor, Podzamczer, Daniel, Olalla, Julián, Vidal, Francesc, Muñoz-Fernández, Mª Angeles, Leal, Manuel, Pacheco, Yolanda M

“…HIV-infected subjects with suboptimal CD4 restoration despite suppressive combined antiretroviral treatment (cART) (immunodiscordant subjects) have been…”
Get full text

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions by Caniglia, Ellen C, Cain, Lauren E, Justice, Amy, Tate, Janet, Logan, Roger, Sabin, Caroline, Winston, Alan, van Sighem, Ard, Miro, Jose M, Podzamczer, Daniel, Olson, Ashley, Arribas, José Ramón, Moreno, Santiago, Meyer, Laurence, del Romero, Jorge, Dabis, François, Bucher, Heiner C, Wandeler, Gilles, Vourli, Georgia, Skoutelis, Athanasios, Lanoy, Emilie, Gasnault, Jacques, Costagliola, Dominique, Hernán, Miguel A

“…OBJECTIVE:The link between CNS penetration of antiretrovirals and AIDS-defining neurologic disorders remains largely unknown. METHODS:HIV-infected,…”
Get full text

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) by Gonzalez-Cao, Maria, Puertolas, Teresa, Riveiro, Mar, Muñoz-Couselo, Eva, Ortiz, Carolina, Paredes, Roger, Podzamczer, Daniel, Manzano, Jose Luis, Molto, Jose, Revollo, Boris, Carrera, Cristina, Mateu, Lourdes, Fancelli, Sara, Espinosa, Enrique, Clotet, Bonaventura, Martinez-Picado, Javier, Cerezuela, Pablo, Soria, Ainara, Marquez-Rodas, Ivan, Mandala, Mario, Berrocal, Alfonso

“…Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or…”
Get full text

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study by Troya, Jesús, Ryan, Pablo, Ribera, Esteban, Podzamczer, Daniel, Hontañón, Victor, Terrón, Jose Alberto, Boix, Vicente, Moreno, Santiago, Barrufet, Pilar, Castaño, Manuel, Carrero, Ana, Galindo, María José, Suárez-Lozano, Ignacio, Knobel, Hernando, Raffo, Miguel, Solís, Javier, Yllescas, María, Esteban, Herminia, González-García, Juan, Berenguer, Juan, Imaz, Arkaitz

“…Based on data from clinical practice, we evaluated the effectiveness and safety of switching to abacavir/lamivudine plus rilpivirine (ABC/3TC+RPV) treatment in…”
Get full text

Long-term efficacy and safety of nevirapine-containing regimens in virologically suppressed patients: a 17-year follow up by Tiraboschi, Juan, Lattour, Natalia, Knobel, Hernando, Domingo, Pere, Ribera, Esteve, Podzamczer, Daniel

“…: To evaluate long term outcomes in patients maintaining a NVP based regimen for more than 10 years. : Retrospective, multicenter, cohort study including…”
Get full text

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study by Troya, Jesús, Ryan, Pablo, Ribera, Esteban, Podzamczer, Daniel, Hontañón, Victor, Terrón, Jose Alberto, Boix, Vicente, Moreno, Santiago, Barrufet, Pilar, Castaño, Manuel, Carrero, Ana, Galindo, María José, Suárez-Lozano, Ignacio, Knobel, Hernando, Raffo, Miguel, Solís, Javier, Yllescas, María, Esteban, Herminia, González-García, Juan, Berenguer, Juan, Imaz, Arkaitz

“…[This corrects the article DOI: 10.1371/journal.pone.0164455.]…”
Get full text

Lack of benefit with omega-3 fatty acid supplementation in HIV patients: A randomized pilot study by Antonio Navarro-Alcaraz, Juan Tiraboschi, Carmen Gómez, Beatriz Candas-Estébanez, María Saumoy, Arkaitz Imaz, Daniel Podzamczer

“…Objective: To assess the effect of omega-3 polyunsaturated fatty acids (n-3 PUFA) supplementation on bone metabolism in HIV-infected patients presenting with…”
Get full text

Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression by Imaz, Arkaitz, Cayuela, Nuria, Niubó, Jordi, Tiraboschi, Juan Manuel, Izquierdo, Cristina, Cabellos, Carmen, Podzamczer, Daniel

“…Monotherapy with boosted protease inhibitors has emerged as an antiretroviral therapy simplification alternative for selected patients, endorsed by the results…”
Get more information

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial by Pollard, Richard B, MD, Rockstroh, Jürgen K, MD, Pantaleo, Giuseppe, MD, Asmuth, David M, MD, Peters, Barry, MD, Lazzarin, Adriano, Prof, Garcia, Felipe, MD, Ellefsen, Kim, MSc, Podzamczer, Daniel, MD, van Lunzen, Jan, MD, Arastéh, Keikawus, MD, Schürmann, Dirk, MD, Clotet, Bonaventura, MD, Hardy, W David, MD, Mitsuyasu, Ronald, MD, Moyle, Graeme, MD, Plettenberg, Andreas, MD, Fisher, Martin, MD, Fätkenheuer, Gerd, MD, Fischl, Margaret, MD, Taiwo, Babafemi, MD, Baksaas, Ingebjørg, PhD, Jolliffe, Darren, MSc, Persson, Stefan, PhD, Jelmert, Øyvind, MSc, Hovden, Arnt-Ove, PhD, Sommerfelt, Maja A, PhD, Wendel-Hansen, Vidar, Dr, Sørensen, Birger, MSc

“…Summary Background Present combination antiretroviral therapy (cART) alone does not cure HIV infection and requires lifelong drug treatment. The potential role…”
Get full text

Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients by VAN DEN EYNDE, Eva, TIRABOSCHI, Juan Manuel, CRESPO, Manuel, TURAL, Cristina, SOLA, Ricard, MIRA, José Antonio, PODZAMCZER, Daniel, JOU, Antoni, CANETE, Nuria, PINEDA, Juan Antonio, PAHISSA, Albert

“…Guidelines recommendation to extend treatment duration in genotype 1 hepatitis C virus (HCV)/HIV-coinfected patients who clear the virus later than treatment…”
Get full text